Hot Features
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic sol... Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer’s disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.24 | -9.48616600791 | 2.53 | 2.6592 | 2.285 | 289801 | 2.45606219 | CS |
| 4 | -0.25 | -9.84251968504 | 2.54 | 2.735 | 2.08 | 322327 | 2.41473469 | CS |
| 12 | -1.04 | -31.2312312312 | 3.33 | 3.6 | 2.08 | 550604 | 2.80065918 | CS |
| 26 | 0.36 | 18.6528497409 | 1.93 | 3.6 | 1.67 | 561746 | 2.58975573 | CS |
| 52 | 1.26 | 122.330097087 | 1.03 | 3.6 | 1 | 470657 | 2.15173929 | CS |
| 156 | -2.9 | -55.8766859345 | 5.19 | 11.3099 | 0.8551 | 437368 | 3.65700008 | CS |
| 260 | -22.78 | -90.8655763861 | 25.07 | 26.98 | 0.8551 | 395008 | 5.30783689 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.